Plexium

Executive Summary

Plexium is a next-generation targeted protein degradation (TPD) company pioneering the discovery of monovalent direct degraders and molecular glues. Based in San Diego, the company was founded in 2017 and has advanced into Phase 1 clinical development, focusing on first-in-class and best-in-class treatments for diseases with high unmet medical needs. Its platform enables the rational design of small molecules that induce degradation of previously undruggable targets, offering potential advantages in selectivity and dosing. While the company remains private and has not disclosed detailed pipeline information, its technology has attracted significant interest, including a partnership with Amgen. Plexium's current stage suggests it is preparing to generate key clinical data that could validate its platform and drive value inflection.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead candidate60% success
• Q4 2026IND filing for second pipeline program70% success
• Q2 2026New strategic partnership or series B/C financing75% success